Tokushukai Medical Group

  • jp
  • en
  • cn
search検索

MENU

CLOSE

<

Academic Activities

Academic

The 1st Tokushukai International Symposium on Regenerative Medicine (RegeMed Kamakura)

Program

Download Abstract Program

December 12, Friday Noontime～
Session-1: Coming Regenerative Medicine13:05~15:25

Chair: Takayuki Asahara (Shonan Kamakura General Hospital, TIMC TOKYO)

  • 1) Vascular regeneration therapy using adipose-derived regenerative cells (ADRC)

    Toyoaki Murohara (Nagoya University)

  • 2) Clinical Experience with Korea’s First iPS Cell-Derived Injectable Chondrospheroid for Osteoarthritis

    Ji Hyeon Ju (The Catholic University of Korea / YiPSCELL)

  • 3) Establishment of Next generation Autologous Tissue and Vascular Regenerative Therapy

    Rica Tanaka (Juntendo University)

  • 4) Toward Next-Generation Regenerative Platforms: Harnessing Small Blood Stem Cells and Stromal Vascular Fraction-Derived Components for Clinical Translation

    Yun Yen (StemBios / Taipei Medical University)

  • 5) Biomedical application of extracellular vesicles

    Takahiro Ochiya (Tokyo Medical University)

Break15:25~15:35
Session-2: Vascular Regeneration in the World15:35~17:35

Chair: Philippe R.G HENON (CellProthera / IRHT)

  • 1) Introduction: Introduction of Biology and Medicine in Vascular Regeneration

    Takayuki Asahara (Shonan Kamakura General Hospital, TIMC TOKYO)

  • 2) Endothelial Progenitor Cells: Current Understanding, Methodological Approaches, and Insights from Single-Cell Technologies.

    Amankeldi Salybekov (Shonan Kamakura General Hospital)

  • 3) Endothelial Cells and Regeneration:A Cornerstone in Hemocompatibility of Cardiovascular Biomaterials

    David Smadja (Paris Cardiovascular research center)

  • 4) Mitochondrial Transfer as a Strategy to Improve ECFC-Based Vascular Therapies

    Juan Melero-Martin (Harvard University / Boston Children’s Hospital)

  • 5) Expanded CD34+ cells (ProtheraCytes®) for treatment of vascular ischemic diseases

    Philippe R.G HENON (CellProthera / IRHT)

Reception Auditorium18:00~
December 13, Saturday Morning～
Session-3: Asian Cell Therapy Now9:00~10:55

Chair: Akihiro Shimosaka (Asian Cell Therapy)

  • Introduction: Importance of Cancer Immune Cell Therapy and application of Exosome derived from Dendritic Cells

    Akihiro Shimosaka (Asian Cell Therapy)

  • 1) A Phase 1 Clinical Trial to evaluate the Safety and Tolerability of Schwann-like cells for Charcot–Marie–Tooth type 1 (CMT1)

    Jaeseung Lim (Cellatoz Therapeutics)

  • 2) JOINT-PRESERVING REGENERATIVE THERAPY: CLINICAL OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC CHONDROCYTE SHEET TRANSPLANTATION

    Masato Sato (Tokai University)

  • 3) Multi-organ single cell transcriptomics for cell-based therapeutic angiogenesis

    Oto Inoue (Kanazawa University)

  • 4) Early results of the clinical trial (LAPiS study) to transplant human iPS cell-derived cardiomyocyte transplantation to severe heart failure due to ischemic heart disease

    Keiichi Fukuda (Keio University, Heartseed Inc.)

Break10:55~11:05
Session-4: Vascular Regeneration Therapy Now11:05~12:10

Chair: Qingbo Xu (Zhejiang University)

  • 1) Tracing CD34+ Cells in the Development and Cardiovascular Diseases

    Qingbo Xu (Zhejiang University)

  • 2) Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34+ cells for acute ischemic stroke patients-A randomized, open-label, controlled phase II clinical trial

    Hon Kan Yip (Kaohsiung Chang Gung Memorial Hospital)

  • 3) Comprehensive cell therapy for kidney disease using autologous G-CSF-mobilized peripheral blood-derived CD34+ cell administration.

    Takayasu Ohtake (Shonan Kamakura General Hospital)

Break before Lunch12:10~12:20
Lunch Session: Vascular Regeneration Therapy Future12:20~13:15

Chair: Juan Melero-Martin (Harvard University / Boston Children’s Hospital)

  • 1) Injectable Vascular organoids generate perfusable blood vessels to alleviate ischemic diseases

    Kai Wang (Pekin University)

  • 2) Generation of liver sinusoidal endothelial-like cells secreting coagulation factor VIII from human iPS cells toward the cell-based therapy for hemophilia A

    Kohei Tatsumi (Nara Medical University)

  • 3) Toward Global Standardization of ECFC-Based Regenerative Therapies: Manufacturing and Regulatory Perspectives

    Chi Young Chang (YOUTH BIO GLOBAL Co., Ltd.)

Break after Lunch13:15~13:30
Session-5: EPC/ECFC Biology Concept13:30~14:40

Chair: David Smadja (Paris Cardiovascular research center)

  • Panel Discussion

    Panelist: David Smadja (Paris Cardiovascular research center)
    Philippe R.G HENON (CellProthera / IRHT)
    Juan Melero-Martin (Harvard University / Boston Children’s Hospital)
    Qingbo Xu (Zhejiang University)
    Takayuki Asahara (Shonan Kamakura General Hospital, TIMC TOKYO)

Speaker Introduction

Keiichi Fukuda
Heartseed
Keio University
After studying abroad at Harvard University, he researched and developed regenerative myocardial medicine as a professor of cardiology at Keio University School of Medicine. He established Heartseed in 2015 and is currently proceeding with clinical trials for iPS cell-derived cardiomyocyte products for heart failure patients. President of the 2020 Annual Meeting of the Japanese Society for Regenerative Medicine.

Ji Hyeon Ju
Catholic University
YiPSCELL
Professor of Rheumatology at Catholic University of Korea. She established Yipcell (a cell therapy venture) and is advancing clinical development research of iPS-derived cells. Clinical studies are currently underway in South Korea.

Toyoaki Murohara
Nagoya University
Professor of Cardiovascular Medicine at Nagoya University School of Medicine. His specialty is cardiovascular medicine, particularly vascular regenerative medicine, vascular biology, and the development of new treatments for heart failure and ischemic heart disease. He is currently advancing clinical application of adipose-derived mesenchymal stem cell therapy. President-elect of the 2025 Annual Meeting of the Japanese Circulation Society.

Takahiro Ochiya
Tokyo Medical University
Specially Appointed Professor at Tokyo Medical University and Visiting Researcher at the National Cancer Center. A world authority on exosome research, ranked No. 1 globally by researcher. He leads application research in cancer metastasis and regenerative medicine, and has received numerous awards. Currently, he is the President of the Japanese Society for Extracellular Vesicles.

Takayuki Asahara
Shonan Kamakura General Hospital
TIMC TOKYO
President of this Symposium. Deputy Director of the Shonan Advanced Medical Research Institute and Director of Tokushukai International Medical Checkup TOKYO. He discovered bone marrow-derived endothelial progenitor cells (EPCs) in 1997 and has been a leader in the fields of vascular regeneration and regenerative medicine.

Rica Tanaka
Juntendo University
Chief Professor of Regenerative Medicine, Professor of Plastic Surgery, and Director of the Foot Disease Center at Juntendo University. She is an expert in vascular regeneration and wound healing. She is advancing clinical application research of autologous cell transplantation therapy for intractable ulcers. Scheduled to be the President of the 2027 Annual Meeting of the Japanese Society for Regenerative Medicine.

David Smadja
Paris Cardiovascular research center
Professor of Hematology at Paris Cité University, affiliated with Georges Pompidou European Hospital. His specialty is hemostasis, thrombosis, and vascular biology. He focuses on endothelial progenitor cell research and is internationally active in the fields of vascular biology and regenerative medicine, including the creation of guidelines for vascular regenerative cells.

Juan Melero-Martin
Harvard University
Boston Children's Hospital
Affiliated with Harvard University and Boston Children's Hospital. He leads vascular regeneration and stem cell research. He has research achievements in vascular regeneration, cardiac surgery using stem cells, and iPS-derived vascular cell differentiation.

Philippe Henon
CellProthera
IRHT,MULHOUSE,France
Former Professor of Medicine at Paris University and Professor of Hematology at the University of Alsace. Specialized in hematology and stem cell research, co-founded CellProthera, and contributed to cardiac regenerative medicine.

Akihiro Shimosaka
Asia Cell Therapy Organization
Chairman of the Asia Cell Therapy Organization. Developed G-CSF and platelet hormone preparations during his time at Kirin Brewery. He is currently active in the fields of regenerative medicine and hematology, and has held administrative and university positions.

Jaeseung Lim
Cellatoz Therapeutics
CEO and CSO of Cellatoz Therapeutics, a Korean biotech company developing regenerative medicine and cell therapies for musculoskeletal and neurological disorders. He holds a Ph.D. from the University of Leeds and has extensive experience in the research and commercialization of stem cell and immunotherapy.

Takayasu Ohtake
Shonan Kamakura General Hospital
Vice Director, Head of Regenerative Medicine Department, and Chief of Renal Immunology and Vascular Medicine Department at the Comprehensive Medical Center for Kidney Diseases at Shonan Kamakura General Hospital. His specialty is kidney disease, dialysis medicine, and regenerative medicine. He has received awards such as the Japanese Kidney Foundation Research Encouragement Award. He is currently advancing multiple clinical studies on vascular regenerative therapy.

Qingbo Xu
Zhejiang University Medical School
Professor at Zhejiang University School of Medicine. Former Professor at King's College London. His specialties are vascular biology, stem cell therapy, and regenerative medicine, and he is globally known for his research on vascular repair and regeneration by EPCs.

Hon-Kan Yip
Kaohsiung Chang Gung Memorial Hospital
Affiliated with Kaohsiung Chang Gung Memorial Hospital, Taiwan. Professor of Cardiology and a pioneer in stem cell therapy, leading clinical research in regenerative medicine for cardiovascular disease and stroke.

Kai Wang
Peking University
Researcher at Peking University School of Basic Medical Sciences. Specialized in interdisciplinary research on stem cells and vascular organoids, pursuing applications in disease modeling and cell therapy. He was a postdoctoral fellow at Harvard Medical School and other institutions.

Chi Young Chang
Youth Bio Global
Chief Scientific Officer at Youth Bio Global. He is advancing research on the development of ECFC culture technology applicable to vascular regenerative therapy, aiming for clinical deployment of the developed product in Korea, Japan, and globally.

Amankeldi Salybekov
Shonan Kamakura General Hospital
Chief Researcher at the Shonan Advanced Medical Research Institute. Participates in regenerative medicine projects at Shonan Kamakura General Hospital. Possesses an international research network.

Kohei Tatsumi
Nara Medical University
Associate Professor of Advanced Medicine for Thrombosis and Hemostasis at Nara Medical University. Specialized in thrombotic-hemostasis and regenerative medicine, researching cell therapy for hemophilia A and the relationship between the coagulation-fibrinolysis system and chronic lung disease/bone metabolism. Also engaged in research on human iPS cell-derived EPCs.

Oto Inoue
Kanazawa University
Assistant Professor of Cardiovascular Medicine at Kanazawa University School of Medicine. Specialized in metabolism and endocrinology. Researches angiogenesis therapy and regenerative medicine using adipose-derived stem cells, etc. Also engaged in research on novel differentiation and metabolic regulatory factors for human iPS cell-derived brown adipose tissue.

Yun Yen
StemBios
Taipei Medical University
Former President of Taipei Medical University. Contributed to cancer research for many years and was elected a Fellow of the Federation of Asian Clinical Oncology (FASCO). Currently conducting basic research and international collaborative research on the application of regenerative medicine stem cells.

Masato Sato
Tokai University
Obtained Ph.D. in Medicine from the Graduate School of Orthopedic Surgery at National Defense Medical College. Since 2013, he has been a Professor of Orthopedic Surgery in the Department of Surgery at Tokai University School of Medicine. He leads the development of musculoskeletal regenerative medicine in Japan and globally, including implementing cartilage regeneration therapy using cell sheets for knee osteoarthritis as Advanced Medical Treatment B, and developing allogeneic cell therapy research.

PAGE TOP

PAGE TOP